Subdural metastases from prostatic adenocarcinoma

Penley, M. W.; Kim, Y.C.; Pribram, H. F. W.

doi:10.1016/0090-3019(81)90114-2

Cited by 22 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, leptomeningeal carcinomatosis secondary to prostatic tumor has been reported, but cranial dural metastases from prostatic adenocarcinoma have been described anecdotally [15][16][17] . Non traumatic subdural hematoma secondary to dural metastases is a rare event.…”

Section: Discussionmentioning

confidence: 99%

Dural metastases with subdural hematoma from prostate cancer

et al. 2005

View full text Add to dashboard Cite

We reported a case of subdural effusion secondary to dural metastasis of prostatic cancer. A 54-year-old man was referred for headache, vomiting and gait disturbance. He had undergone hormonal therapy and docetaxelbased chemotherapy for prostatic cancer. The magnetic resonance imaging of the brain showed extensive leptomeningeal carcinomatosis and cranial dural metastases, and subdural hematoma. This is a very rare situation and bad prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Dural metastases with subdural hematoma from prostate cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…More specifically, metastasis to the dura mater has rarely been reported in prostate cancer literature, with only sporadic mention found in case reports and autopsy series. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] Penley et al 5 reported the first case of discrete DM from prostate adenocarcinoma in 1981, and since then, there have been 14 other case reports of DM from prostate cancer in the literature, [6][7][8][9][10][11][12][13][14][15][16][17][18] with additional cases mentioned only briefly in autopsy series. [19][20][21] Presented here, to the authors' knowledge, is the first case series (n ¼ 10) of DM diagnosed ante-mortem in patients with metastatic prostate cancer, with a review of the relevant literature.…”

mentioning

confidence: 99%

Presentation, Treatment, and Outcomes of Dural Metastases in Men with Metastatic Castrate-Resistant Prostate Cancer: A Case Series

Lawton

Sudakoff

Dezelan

et al. 2010

Journal of Palliative Medicine

View full text Add to dashboard Cite

Purpose: Men with metastatic castrate-resistant prostate cancer (mCRPC) have shown increased survival since the introduction of docetaxel-based chemotherapy in 2004. While bone metastases are common in prostate cancer, cranial dural metastases (DM) are not. We hypothesize that longer survival in patients with mCRPC may increase the incidence of uncommon metastatic sites, including the cranial dura. We describe 10 cases of DM in men with mCRPC and review the relevant literature. Materials and Methods: We conducted a retrospective chart review of 10 subjects with mCRPC, diagnosed antemortem with DM at our institution between August 1, 2003 and June 1, 2008. Variables analyzed included prognostic factors at prostate cancer diagnosis, number of therapies prior to DM, treatments administered for DM with response achieved, and survival following diagnosis of DM. Results: Median age at prostate cancer diagnosis was 59 years (range, 52-80), with a median Gleason's score of 9 (range, 8-10) and prostate-specific antigen (PSA) of 37 ng/dL (range, 4.9-118). Fifty percent had metastatic disease at initial diagnosis. A median of 5 therapies (range, 1-13) were administered prior to diagnosis of DM, including a median of 1 course of chemotherapy (range, 1-3). Cranial neuropathies were the most common presenting symptoms of DM, and 8 of 10 patients received treatment for their DM, most often radiotherapy. Median survival for this group was 6.17 months (range, < 1-15). Conclusions: Treatment advances in mCRPC may lead to an increased incidence of previously rare metastatic sites. CNS symptoms in men with mCRPC should prompt evaluation for DM.

show abstract

Intracranial metastases due to prostatic carcinoma

Castaldo

Bernat

Meier

et al. 1983

Cancer

View full text Add to dashboard Cite

From 1973 to 1982, 189 patients were treated at the Dartmouth‐Hitchcock Medical Center for Stage C or D prostatic carcinoma. In eight of these cases (4.2%), there was clinical or pathological evidence for intracranial metastases. The condition of subdural neoplastic spread, not from contiguous bone, was identified in five cases, two of which were suspected before death. Four of these five patients were thrombocytopenic or pancytopenic at the time of the diagnosis. Intraparenchymal brain metastases were identified in six cases. Cerebellar, temporal bone, cavernous sinus, and splenium infiltration by tumor were unusual findings in individual cases. The results of chest x‐rays and respiratory status were poor predictors of lung metastases in four of five patients on whom autopsies were performed. This article describes the spectrum of radiographic and pathologic findings of intracranial prostatic carcinoma, and suggests that the likely mechanism of brain metastasis in these cases is by the dural veins and Virchow‐Robin spaces.

show abstract

Subdural metastases from prostatic adenocarcinoma

Cited by 22 publications

References 6 publications

Dural metastases with subdural hematoma from prostate cancer

Dural metastases with subdural hematoma from prostate cancer

Presentation, Treatment, and Outcomes of Dural Metastases in Men with Metastatic Castrate-Resistant Prostate Cancer: A Case Series

Intracranial metastases due to prostatic carcinoma

Contact Info

Product

Resources

About